SCHEMBL90429

SCHEMBL90429

CCOCCN1C(=O)C(C)(C)Oc2ccc(N(C(=O)[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H](C(=O)OC)[C@H]3O)C3CC3)cc21

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PDE4B Q07343 3/20 0.34
ALDH1A1 P00352 5/20 0.33
POLB P06746 2/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
USP2 O75604 2/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
GPR119 Q8TDV5 1/20 0.32
HPGD P15428 1/20 0.32
MAPT P10636 1/20 0.32
RECQL P46063 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90391 0.93 REN (0.34) RENCYP1A2CYP2C9CYP2C19PDE4B
SCHEMBL90380 0.91 REN (0.38) RENCYP1A2CYP2C9CYP2C19PDE4B
SCHEMBL90631 0.89 REN (0.41) RENCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL90425 0.87 REN (0.47) RENALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL90135 0.85 REN (0.37) RENCYP1A2CYP2C9CYP2C19PDE4B
SCHEMBL90629 0.84 REN (0.39) RENCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL90385 0.83 REN (0.41) RENCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL89776 0.83 REN (0.55) RENALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL90108 0.82 REN (0.40) RENCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL8235850 0.82 REN (0.40) RENCYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2420491-B1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2013-07-03 EP disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 REN 1/4885CYP1A2 239/4885CYP2C9 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.